Advances in Pseudoprogression of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer

TL;DR

This paper reviews the challenges of pseudoprogression in non-small cell lung cancer patients treated with immune checkpoint inhibitors, focusing on its impact on clinical assessment and the need for better diagnostic tools.

Contribution

The paper provides a comprehensive review of current research on pseudoprogression in NSCLC, highlighting gaps in understanding and clinical management.

Findings

Pseudoprogression can lead to temporary tumor size increases or new lesions, but often improves with continued treatment.

There is a lack of reliable biomarkers and predictive factors for identifying pseudoprogression early.

Current radiological criteria are insufficient for accurately assessing immune responses in these patients.

Abstract

免疫检查点抑制剂的出现极大地改善了晚期肺癌患者的预后，但其可能会导致假性进展，使临床评估和管理变得复杂化。假性进展表现为肿瘤暂时性增大或出现新病变等，继续治疗后影像学上出现改善，多不伴有临床症状恶化。目前假性进展在早期诊断方面仍存在困难，其发生机制尚不明确，缺乏良好的预测因素和相关生物标志物。本文通过对非小细胞肺癌免疫检查点抑制剂假性进展的研究现状进行综述，以期为使用该类药物治疗患者的临床医生提供有益的参考。

Radiological criteria in assessment of immune responses

Studies of PsP in NSCLC